Healthcare
Biotech player CANbridge drops on debut after $87m HK IPO
CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses on treatments for cancer and rare diseases, lost 27% in value on its Hong Kong trading debut following a HK$685.1 million ($87.8 million) IPO.
China’s ABclonal Technology raises $189m
Chinese life science research and diagnostic reagents provider ABclonal Technology has raised a RMB1.2 billion ($189 million) Series D round featuring Sequoia Capital China.
Singapore's Aura acquires Australia vaccination player
Singapore-based Aura Private Equity has acquired a majority stake in Australian Vaccine Services (AVS), a leading provider of corporate flu vaccinations.
China surgical robotics player RainMed raises $100m
Ping An Capital has led a Series D round of approximately $100 million for RainMed Medical, a China-based surgical robotics business. Other investors include Seresia Asset Management and Lighthouse Canton.
Korea anti-aging polymer maker gets $22m
Dexlevo, a Korean biotech company specializing in anti-aging dermal fillers, has raised KRW26 billion ($22 million) in pre-IPO funding led by local GPs Magna Investment and Smilegate Investment.
Blue Sky spinout backs Australia cosmetic medical business
Fortitude Investment Partners, an Australia-based private equity firm established by professionals from Blue Sky Alternative Investments, has backed cosmetic medical business Aura Medical Group.
Horizons leads Series B for Australia healthcare AI start-up
Horizons Ventures, the private investment arm of Hong Kong billionaire Li Ka-Shing, has led a A$129 million ($92.3 million) Series B round for Australia’s Harrison.ai, a clinical artificial intelligence (AI) developer.
Vision Fund joins $300m round for China vaccine developer
SoftBank Vision Fund 2 and 5Y Capital have led a $300 million Series C extension for Suzhou Abogen Biosciences, a Chinese vaccine developer focused on mRNA products, including one for COVID-19.
Portfolio: Dymon Asia and AMES
For all the hubbub about digital businesses taking flight during the pandemic, few categories saw as much upside as traditional medical waste disposal. Dymon Asia Private Equity is enjoying the ride
Legend hits first close on healthcare fund, launches TMT vehicle
Legend Capital has reached a first close of $177 million on its third US dollar-denominated China healthcare fund. It is one of five vehicles the GP has in the market, including its recently launched ninth flagship technology, media, and telecom (TMT)...
Qiming leads $40m round for Allorion Therapeutics
China and US-based precision medicine company Allorion Therapeutics has raised a $40 million Series A round led by Qiming Venture Partners.
China biotech IPOs in Hong Kong to stay strong - AVCJ Forum
The frenzy for Chinese biotech developers listing in Hong Kong is expected to continue well into 2022, industry participants told the AVCJ Private Equity & Venture Forum.
Bain leads $69m Series C for Japan's Linc'well
Bain Capital has led a JPY8 billion ($69 million) Series C round for Linc’well, a Japan-based software-as-a-service (SaaS) provider that caters to medical institutions.
China ocular drugs developer raises $63m
China’s Neurophth Biotechnology, a gene therapy developer for ocular diseases, has raised a RMB400 million ($63 million) Series C round led by SDIC China Merchants Investment and Sequoia Capital China.
Deal focus: Icon retains its private equity appeal
EQT’s $1.67 billion acquisition of Icon Group underscores the recent trend in large-cap buyouts, as well as the long-term growth potential for cancer care specialists in Australia and the wider Asian region
EQT buys Australia cancer care business from PE consortium
Goldman Sachs Asset Management, QIC, and Pagoda Investment – a China-focused GP set up by a former QIC executive – have agreed to sell Australia cancer care provider Icon Group to EQT for a reported valuation of A$2.3 billion ($1.67 billion).
CBC, APG launch China healthcare infra fund
Specialist healthcare investor CBC Group has teamed up with APG Asset Management to launch a $1.5 billion fund dedicated to the development of healthcare infrastructure in China.
Japan's Olympus launches VC unit, $50m fund
Japan’s Olympus Corporation has launched a medical technology-focused venture capital unit, Olympus Innovation Ventures, with an initial commitment of $50 million for its debut fund.
Riverside backs Australia clinical trials business
The Riverside Company has acquired Avance Clinical, an Australia-based contract research organization (CRO) with a view to building out its clinical trials business.
GL Capital leads $125m round for Hzymes Biotechnology
Wuhan-based Hzymes Biotechnology, a specialized enzymes developer, has raised RMB800 million ($125 million) in Series C funding led by healthcare specialist GL Capital
China CRO Tripod raises $156m
Tripod Preclinical Research Laboratories, a China-based contract research organization (CRO) based in Nanjing, has raised RMB1 billion ($156 million) led by Ruihua Capital, Lilly Asia Ventures (LAV) and GL Ventures.
Fund focus: Genesis reinforces Australia’s specialist thesis
Having raised $142 million for its debut fund, Genesis Capital joins a select group of Australian mid-market GPs with blind pools. The firm believes a singular focus on healthcare was a key selling point
3H Healthcare closes second US dollar fund at $330m
3H Healthcare Investment, which specializes in early-stage China biotech and medical devices deals, has closed its second US dollar-denominated fund at the hard cap of $330 million.
Blackstone buys Australia clinical trials specialist
The Blackstone Group has acquired Nucleus Network, which claims to be Australia’s largest phase-one clinical trials provider, for an undisclosed sum. It provides an exit for local GP Crescent Capital Partners.